Attractive tax inversion targets remain, analysts say

Bloomberg reports that, according to analysts, there are three ex-U.S. medical firms that should be high on the target acquisition list for tax inversion deals. Ireland-based Perrigo (NYSE:PRGO), Switzerland-based Actelion and U.K.-based Smith & Nephew Plc (NYSE:SNN) (OTCQB:SNNUF) are all attractive targets. Observers believe there will be more acquisitions consummated before Congress puts limits on the maneuvers.

Stryker (NYSE:SYK) has been mentioned as a potential suitor for Smith& Nephew. Pfizer (NYSE:PFE) may make another run at AstraZeneca (NYSE:AZN) after the end of the cool-off period.

From other sites
Comments (1)
  • glenkaiser06
    , contributor
    Comments (47) | Send Message
    Sounds like a good fit. SNN jumped on friday, probably in anticipation of this Bloomberg report. SYK bought MAKO last year which seemed like a questionable investment since MAKO had real problems making money and resurfacing of the knee & hip has very limited application. SNN makes more sense even if there is a lot of overlap. However SNN isn't really looking for a white knight, they have aggressive expansion plans of their own.
    21 Jul 2014, 07:57 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs